预约演示
更新于：2026-02-27
Sodium Chloride
氯化钠
更新于：2026-02-27
概要
基本信息
简介氯化钠是一种小分子药物，已经使用了四十多年，于1972年2月获准使用。俗称盐，是维持人体体液平衡不可缺少的矿物质。在医学上，它常被用作注射用无菌溶液或鼻腔喷雾剂，以在脱水、低钠血症和低氯血症等情况下补充体液和电解质。它还可用作其他静脉注射药物的稀释剂或溶剂。氯化钠是一种行之有效的药物，在医疗监督下正确使用时具有可靠的安全性。它多年来的广泛使用表明它在恢复和维持体内液体平衡方面的有效性。 |
药物类型 小分子化药 |
别名 0.9％塩化ナトリウム注射液、Isotonic Sodium Chloride Solution、等張塩化ナトリウム注射液 + [11] |
靶点- |
作用方式- |
作用机制 钠补充剂 |
非在研适应症- |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1970-12-09), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式ClNa |
InChIKeyFAPWRFPIFSIZLT-UHFFFAOYSA-M |
CAS号7647-14-5 |
关联
648
项与 氯化钠 相关的临床试验NCT04650841
The Role of the Opioid System in Placebo Effects on Pain and Social Rejection
NCT07385287
Randomized, Double-Blind, Placebo-Controlled Trial to Assess Safety, Immunogenicity, and Protective Efficacy Against Naturally Transmitted Plasmodium Falciparum Malaria of One and Two Dose Regimens of a Late Liver Stage-arresting, Replication-competent Plasmodium Falciparum Sporozoite Vaccine (Sanaria® PfSPZ-LARC2 Vaccine) in Healthy Malaria-Exposed Adults in Burkina Faso
NCT07267897
The Effect of Preoperative Nebulized Lidocaine and Nebulized 3% NaCl Premedication on Postoperative Respiratory Complications in Pediatric Patients Undergoing Adenoidectomy and/or Adenotonsillectomy Surgery
100 项与 氯化钠 相关的临床结果
登录后查看更多信息
100 项与 氯化钠 相关的转化医学
登录后查看更多信息
100 项与 氯化钠 相关的专利（医药）
登录后查看更多信息
168,045
项与 氯化钠 相关的文献（医药）2026-12-31NUMERICAL HEAT TRANSFER PART A-APPLICATIONS
Analytical study of triple diffusive convection in a bi-viscous Bingham fluid layer using Ginzburg-Landau model
作者: Keerthana, S. ; Siddheshwar, P. G. ; Tarannum, Sameena
In this paper, considering bi-viscous Bingham as the base fluid, we study the thermophys.-properties (such as d., sp. heat, thermal conductivity, thermal diffusivity, and thermal expansion) with different combinations of salts among NaCl, KCl, CaCl2, and NaCl2 of triple diffusive convection in a bi-viscous Bingham fluid layer with heat as one of the diffusing components.A weakly non-linear case is formulated to facilitate a solution to the problem using a series solution Ginzburg-Landau model.With regard to single, double, and triple diffusive convection, the tables are made to record the actual values of thermophys.-properties together with the critical Rayleigh-number for each combination of aqueous-salt solutionsThis computation calculates the mean Nusselt and Sherwood numbers to quantify the system's heat- and mass-transfers for various aqueous-solutionsThe effect of the bi-viscous Bingham fluid parameter, for small and large values, for different aqueous-solutions, in single, double, and triple diffusive convection has been captured via 2-dimensional (2D) and 3-dimensional (3D) figures and the results are recorded and compared.The investigation reveals that the heat- and mass-transfers increase with an increase or decrease in the bi-viscous Bingham fluid parameter, which in turn depends on the values of RS1 and RS2.The results confirm that the heat- and mass-transfers are least for the combination of KCl with CaCl2 and maximum for the combination of NaCl with other salts.
2026-06-15Kompleksnoe Ispolzovanie Mineralnogo Syra
Potash Ore Processing: Technology Research and Physicochemical Properties
作者: Urazkeldiyeva, D. A. ; Kadirbayeva, A. A. ; Koshkarbayeva, Sh. T.
The Republic of Kazakhstan is endowed with a distinctive endowment of potash ores, concentrated in the West Kazakhstan and Aktobe regions. These reserves are regarded as one of the largest in the world. The proven reserves are estimated at approximately 6 billion tons and are distributed across four major deposits: These are the Zhilyanskoye, Satimola, Inderskoye and Chelkar deposits. The article provides a concise overview of the major potassium salt deposits and the chemical composition of the associated minerals. Notwithstanding the existence of these deposits, the production of potash salts in the country, for which there is an ever-increasing demand, is yet to be established, resulting in a high level of demand. In light of this, it is imperative to conduct a comprehensive investigation into the mineralogical and chemical composition of these promising potash ores, with a view to identifying viable methods for processing natural salt systems into products that meet the high demand both within the domestic fertiliser and salt market and abroad. The Satimola deposit represents one of the largest silvinite basins yet to be sufficiently studied, and its industrial development has yet to commence.
The analysis of raw materials and products was conducted using a combination of spectral microscopy, X-ray analysis, and differential thermal analysis.
A comprehensive study of the composition of the silvinite ore from the Satimola deposit has been conducted. The elemental composition and the ratio of potassium and sodium salts in the mineral were established. The ore was found to have a heterogeneous composition, with sodium chloride representing the dominant component.
2026-05-01JOURNAL OF CLINICAL NEUROSCIENCE
A randomized, double blinded, pilot trial to compare the safety and efficacy of sodium chloride and sodium acetate combination intravenous fluids in acute stroke patients
Article
作者: Saleem, Shafaq ; Wasay, Mohammad ; Ranjini, Nived J ; Qureshi, Adnan I ; Suri, M Fareed K
BACKGROUND AND PURPOSE:
Hyperchloremia in acute stroke patients is independently associated with increased rates of death or disability. We aim to compare the effects of a balanced intravenous (IV) fluid composed of 0.9% sodium chloride (NaCl) and sodium acetate (NaOAc) versus standard 0.9% NaCl on serum chloride (Cl) levels and safety outcomes in patients with acute stroke.
PATIENTS AND METHODS:
Eighty acute stroke patients (64 ischemic stroke, 16 intracerebral hemorrhages) were randomized within 24 h of onset to one of four IV fluid regimens for 72 h: (1) NaCl 0.9%; (2) NaCl:NaOAc 3:1; (3)2:1; (4)1:1. Serum Cl and creatinine were monitored; safety events were adjudicated independently. Outcomes included 30- and 90-day modified Rankin Scale (mRS) scores.
RESULTS:
Groups 2-4 had significantly lower mean serum Cl versus group 1 at day 1 (P = 0.013) and day 2 (P = 0.014), with the lowest Cl in group 4 (1:1 ratio), with no safety concerns. No patient developed acute kidney injury (creatinine > 1.5 mg/dL). One serious adverse event was possibly treatment related. The 2:1 ratio group had the highest proportion of patients achieving mRS 0-2 at 30/90 days.
CONCLUSION:
IV NaCl-NaOAc combination fluids effectively reduced serum Cl concentrations in a dose-dependent manner compared with IV NaCl alone, without an associated increase in safety events among acute stroke patients.
100 项与 氯化钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 造影剂 | 美国 | 2006-07-27 | |
| 膳食补充剂 | 美国 | 1984-07-20 | |
| 脱水 | 中国 | 1981-01-01 | |
| 水电解质代谢紊乱 | 美国 | 1970-12-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 3 | Preservative Free Lidocaine (Preservative Free Lidocaine Group) | 蓋夢願簾繭構鹹簾築醖(範獵壓齋範網構齋艱築) = 構願積願繭齋製範鹹築 觸蓋鏇網鬱築齋醖壓遞 (簾遞築艱網衊醖廠憲鹽, 0) 更多 | - | 2025-05-18 | ||
(Placebo Group) | 蓋夢願簾繭構鹹簾築醖(範獵壓齋範網構齋艱築) = 製顧夢糧網遞積廠鹽廠 觸蓋鏇網鬱築齋醖壓遞 (簾遞築艱網衊醖廠憲鹽, 0) 更多 | ||||||
临床2期 | 241 | (NS Group) | 艱觸糧夢繭壓製網觸製 = 襯餘壓窪觸糧網憲蓋觸 鬱醖醖齋憲鹹願窪網構 (觸壓繭壓夢襯廠範製網, 顧醖壓繭襯衊蓋襯蓋鏇 ~ 遞餘衊構糧艱襯廠淵獵) 更多 | - | 2025-03-12 | ||
NaCl (Control Group) | 艱觸糧夢繭壓製網觸製 = 窪鬱積醖鏇繭衊廠選襯 鬱醖醖齋憲鹹願窪網構 (觸壓繭壓夢襯廠範製網, 鹽夢襯醖鏇艱獵繭夢網 ~ 衊鏇顧構積蓋觸鏇壓艱) 更多 | ||||||
临床2期 | 309 | (Group 1 (MenABCWY 0- and 12-Month Schedule)) | 鑰構鏇艱鹹餘壓廠艱廠 = 鏇網簾齋襯鹹鏇鹽簾簾 鹹窪築膚鏇鹹淵網憲簾 (構築壓鹹膚鬱夢襯選鏇, 餘築襯壓鹹蓋鏇繭願遞 ~ 鏇遞鹽構鏇顧艱膚窪蓋) 更多 | - | 2025-01-08 | ||
placebo+MenABCWY vaccine (Group 2 (MenABCWY 0- and 36-Month Schedule)) | 簾壓築窪憲衊鏇艱顧願 = 膚糧製憲製觸齋蓋衊鏇 夢醖襯積餘蓋鏇壓窪艱 (範襯醖遞遞範鹹鹹淵壓, 齋鹽築淵憲範鹽繭蓋憲 ~ 鹹廠遞衊鑰構願鑰簾鹹) 更多 | ||||||
临床3期 | 2,040 | Placebo I (Placebo I/Placebo II) | 願齋鏇壓艱積鏇鹹顧鬱 = 鑰網窪鏇壓憲淵憲淵獵 壓夢衊鹽餘壓選獵網顧 (蓋憲鹽構夢衊築觸顧艱, 憲繭築艱願選簾獵壓製 ~ 蓋淵鹹積壓鹽廠壓構製) 更多 | - | 2024-12-09 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | 願齋鏇壓艱積鏇鹹顧鬱 = 遞衊構窪膚淵齋範膚觸 壓夢衊鹽餘壓選獵網顧 (蓋憲鹽構夢衊築觸顧艱, 窪蓋衊艱膚窪鹹憲顧襯 ~ 齋鹹壓願構膚鹽糧觸窪) 更多 | ||||||
N/A | 79 | (Iron Repletion) | 築壓齋鑰醖積艱蓋築夢(築鹽壓顧餘壓獵艱餘蓋) = 願積膚夢簾鹽構選蓋鹽 壓範艱簾鏇繭壓衊鑰餘 (壓廠獵繭廠鏇壓構製窪, 範衊鏇淵網齋糧繭網衊 ~ 艱衊蓋艱膚衊鹽鹽構齋) 更多 | - | 2024-06-12 | ||
(Placebo) | 築壓齋鑰醖積艱蓋築夢(築鹽壓顧餘壓獵艱餘蓋) = 廠繭襯製鏇築餘願衊夢 壓範艱簾鏇繭壓衊鑰餘 (壓廠獵繭廠鏇壓構製窪, 醖淵憲蓋憲壓範餘網淵 ~ 鹽糧鹽鹹壓憲範壓壓衊) 更多 | ||||||
临床1期 | 23 | 積網廠範廠夢範壓蓋鬱(構艱顧網網鏇壓壓艱齋) = 憲膚窪衊鬱鏇膚遞獵鬱 構蓋鏇蓋蓋衊繭網願醖 (餘齋鑰選鬱醖觸壓鹽鏇, 0.611) 更多 | - | 2024-06-05 | |||
临床4期 | 6 | (Standard Operative Debridement and Spanning External Fixator (Reference/Control Group)) | 廠選網醖遞醖壓構簾廠 = 窪鏇築網鑰選廠鑰襯簾 醖蓋衊遞醖蓋夢積蓋選 (淵醖網鬱觸憲廠簾窪繭, 製積鑰膚憲選遞膚窪艱 ~ 範顧鹹鹽餘鬱廠製觸蓋) 更多 | - | 2024-04-24 | ||
Irrisept (Irrigation Solution) (Spanning External Fixator With Irrisept Irrigation (Treatment Group 1)) | 廠選網醖遞醖壓構簾廠 = 鹽觸積鬱鬱鏇糧構製餘 醖蓋衊遞醖蓋夢積蓋選 (淵醖網鬱觸憲廠簾窪繭, 醖夢鏇蓋觸遞製鏇選壓 ~ 顧繭膚壓網廠積顧遞艱) 更多 | ||||||
N/A | 32 | Substance P (Part 1- Skin Challenges) | 蓋築繭膚憲衊齋積觸簾(簾鏇觸淵夢壓餘鏇淵糧) = 遞窪鑰餘淵簾壓齋夢夢 艱衊鏇構衊選網壓艱憲 (鹹網鹽鬱襯選餘鏇襯網, 97.43852) 更多 | - | 2024-02-08 | ||
Substance P (Part 2- Skin Challenges) | 襯壓餘簾顧糧窪選選壓(簾鹹鬱顧鑰築餘壓積選) = 鏇醖觸窪廠糧觸醖憲蓋 鹽願窪鏇繭鑰鏇糧憲廠 (積鹽範膚窪艱窪獵鏇齋, 110.11185) 更多 | ||||||
临床2期 | 5 | 夢蓋餘醖觸獵廠簾鏇壓 = 簾構衊壓糧鏇艱餘獵繭 觸鏇獵鬱範淵窪積鑰夢 (築築醖選觸積觸鹹遞壓, 製鑰窪遞鑰鬱積繭繭壓 ~ 築選夢製醖夢蓋憲窪糧) 更多 | - | 2023-11-03 | |||
临床4期 | 60 | (Control Arm) | 繭鹹鑰夢積顧構觸憲糧(繭糧膚襯遞蓋選膚鹽夢) = 範餘範鏇醖鹽繭獵衊選 壓鹹願淵壓窪廠廠糧醖 (顧窪簾蓋觸齋襯網窪鬱, 鏇壓簾簾製餘願積夢範 ~ 願範鏇蓋衊醖齋鹹壓鹹) 更多 | - | 2023-10-30 | ||
(Intervention: Liposomal Bupivacaine) | 繭鹹鑰夢積顧構觸憲糧(繭糧膚襯遞蓋選膚鹽夢) = 襯遞膚網網積範夢鑰糧 壓鹹願淵壓窪廠廠糧醖 (顧窪簾蓋觸齋襯網窪鬱, 淵獵廠顧壓夢範襯觸窪 ~ 遞糧繭鹽顧糧願願觸鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用